FDA to rule this week on Incyte's bid for wider use of Jakafi

The Food and Drug Administration is expected to rule late this week on Incyte Corp. ’s effort to get a wide approval for its flagship Jakafi medication. Jakafi is already approved as a treatment for polycythemia vera, a chronic type of bone marrow disease, and for people with intermediate or high-risk myelofibrosi, a group of rare cancers of the bone marrow. The Wilmington-base d biotechnology has filed a supplemental new drug application to expand those uses to include treating patients with acute…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news